List of works - Lynnette Fernandez-Cuesta

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

article

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

scientific article published on 27 December 2016

CD74-NRG1 fusions in lung adenocarcinoma

scientific article published on 27 January 2014

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

scientific article

Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas

scientific article published on 07 January 2021

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach

scientific article published on 20 September 2019

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

scientific article

Genomic architecture of lung cancers.

scientific article

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

scientific article published on June 2016

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes

scientific article published on 30 July 2018

Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer

scientific article

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

scientific article

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

scientific article published on 20 August 2019

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

scientific article published on 13 March 2018

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

scientific article

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

scientific article

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

scientific article

Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data

scientific article published on 20 April 2020

New insights into the molecular characteristics of pulmonary carcinoids and large-cell neuroendocrine carcinomas, and the impact on their clinical management.

scientific article published on 14 February 2018

Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease

Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas.

scientific article

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations

scientific article published on 11 December 2015

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines

scientific article published on April 2011

List of works by Lynnette Fernandez-Cuesta

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

CD74-NRG1 fusions in lung adenocarcinoma

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas

EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach

Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids

Genomic architecture of lung cancers.

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes

Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer

Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data

Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data

New insights into the molecular characteristics of pulmonary carcinoids and large-cell neuroendocrine carcinomas, and the impact on their clinical management.

Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease

Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas.

Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations

p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines